Quantcast
Last updated on April 17, 2014 at 17:30 EDT

Latest MiMedx Group Inc. Stories

2013-09-24 16:25:41

MARIETTA, Ga., Sept. 24, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that Dr. Gary Stanziano has joined MiMedx as the Company's Vice President of Medical Affairs. In his new role, Dr. Stanziano will focus primarily on interfacing with health plans to facilitate broader reimbursement for MiMedx products....

2013-09-18 12:31:20

MARIETTA, Ga., Sept. 18, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has been selected to Georgia's 2013 Top 100 Public Companies. This prestigious list is sponsored by GeorgiaTrend Magazine and determined by S&P Capital IQ, a part of McGraw Hill Financial. The 2013 list is based on fiscal year...

2013-09-12 12:29:03

MARIETTA, Ga., Sept. 12, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that the Company has a meeting scheduled with the Food and Drug Administration ("FDA") to discuss the recent Untitled Letter it received from that agency. The FDA has scheduled the meeting for October 16, 2013. Parker H. Petit, Chairman...

2013-09-09 08:28:48

MARIETTA, Ga., Sept. 9, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the Stifel Healthcare Conference 2013 in Boston, Massachusetts. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to...

2013-09-04 20:21:37

MARIETTA, Ga., Sept. 4, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will host a conference call on Thursday, September 5, 2013 at 11 am Eastern Time to discuss its recent press release regarding the receipt of an "Untitled Letter" from the Food and Drug Administration ("FDA") and the reiteration of...

2013-09-04 16:27:34

MARIETTA, Ga., Sept. 4, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, confirmed today that it is in receipt of an "Untitled Letter" from the Food and Drug Administration ("FDA"). The Company further announced that it expressly disagrees with the position in the letter and has been in conversation with the FDA to resolve the...

2013-08-20 08:31:13

MARIETTA, Ga., Aug. 20, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Prospective, Randomized, Blinded, Comparative Study of Injectable Micronized Dehydrated Amniotic/Chorionic Membrane Allograft for Plantar Fasciitis--A Feasibility Study" has been electronically published in the journal, Foot...

2013-08-05 08:28:57

MARIETTA, Ga., Aug. 5, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it will present at the 33(rd) Annual Canaccord Genuity Growth Conference in Boston. Parker H. "Pete" Petit, Chairman and CEO, William C. Taylor, President and COO, and Michael J. Senken, Chief Financial Officer, are scheduled to...

2013-08-01 16:30:16

MARIETTA, Ga., Aug. 1, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that its study "Biological Properties of Dehydrated Human Amnion/Chorion Grafts: Implications for Chronic Wound Healing" has been electronically published in the International Wound Journal. The electronic publication of the study is...

2013-07-31 08:29:11

MARIETTA, Ga., July 31, 2013 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today its results for the quarter ended June 30, 2013. Highlights of second quarter 2013 results include: Revenue met or exceeded forecast for 7th consecutive quarter Revenue increased more than 175% over second quarter of 2012 Six-month...